hh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Therapeutic vaccination of active arthritis with a glycosylated collagen type II peptide in complex with MHC class II molecules
Lund University, Lund, Sweden.
Lund University, Lund, Sweden.ORCID iD: 0000-0001-7790-8197
Umeå University, Umeå, Sweden.
University of Oxford, Oxford, United Kingdom.
Show others and affiliations
2006 (English)In: Journal of Immunology, ISSN 0022-1767, E-ISSN 1550-6606, Vol. 176, no 3, p. 1525-1533Article in journal (Refereed) Published
Abstract [en]

In both collagen-induced arthritis (CIA) and rheumatoid arthritis, T cells recognize a galactosylated peptide from type II collagen (CII). In this study, we demonstrate that the CII259-273 peptide, galactosylated at lysine 264, in complex with Aq molecules prevented development of CIA in mice and ameliorated chronic relapsing disease. In contrast, nonglycosylated CII259-273/Aq complexes had no such effect. CIA dependent on other MHC class II molecules (Ar/Er) was also down-regulated, indicating a bystander vaccination effect. T cells could transfer the amelioration of CIA, showing that the protection is an active process. Thus, a complex between MHC class II molecules and a posttranslationally modified peptide offers a new possibility for treatment of chronically active autoimmune inflammation such as rheumatoid arthritis. © 2006 by The American Association of Immunologists, Inc.

Place, publisher, year, edition, pages
Rockville, MD: American Association of Immunologists , 2006. Vol. 176, no 3, p. 1525-1533
Keywords [en]
Animals, Arthritis, Experimental/chemically induced/immunology/*prevention & control, Bystander Effect/immunology, Cattle, Chronic Disease, Collagen Type II/immunology/metabolism/*therapeutic use, Galactose/metabolism, Glycosylation, Histocompatibility Antigens Class II/immunology/metabolism/*therapeutic use, Hybridomas/immunology/metabolism, Immunodominant Epitopes/immunology/metabolism/therapeutic use, *Immunotherapy, Active, Lymphocyte Activation/drug effects/immunology, Male, Mice, Mice, Inbred BALB C, Multiprotein Complexes/immunology/metabolism/*therapeutic use, Peptides/immunology/metabolism/*therapeutic use, Rats, Solubility, T-Lymphocytes/drug effects/immunology, Vaccines/immunology/*therapeutic use
National Category
Immunology in the medical area Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:hh:diva-48829DOI: 10.4049/jimmunol.176.3.1525ISI: 000234766600030PubMedID: 16424181Scopus ID: 2-s2.0-31144450506OAI: oai:DiVA.org:hh-48829DiVA, id: diva2:1719046
Available from: 2022-12-14 Created: 2022-12-14 Last updated: 2023-02-16Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Nandakumar, Kutty Selva

Search in DiVA

By author/editor
Nandakumar, Kutty Selva
In the same journal
Journal of Immunology
Immunology in the medical areaRheumatology and Autoimmunity

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 39 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf